IN2015DN03203A - - Google Patents

Info

Publication number
IN2015DN03203A
IN2015DN03203A IN3203DEN2015A IN2015DN03203A IN 2015DN03203 A IN2015DN03203 A IN 2015DN03203A IN 3203DEN2015 A IN3203DEN2015 A IN 3203DEN2015A IN 2015DN03203 A IN2015DN03203 A IN 2015DN03203A
Authority
IN
India
Prior art keywords
binding agent
impurities
mixture
cytotoxic agent
cell
Prior art date
Application number
Inventor
Xinfang Li
Wenjie Cheng
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of IN2015DN03203A publication Critical patent/IN2015DN03203A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

The invention provides processes for preparing purified cell- binding agent cytotoxic agent conjugates comprising subjecting a mixture comprising a cell- binding agent cytotoxic agent conjugate and one or more impurities to an ion exchange chromatography membrane to remove at least a portion of the impurities from the mixture, thereby providing a purified cell- binding agent cytotoxic agent conjugate.
IN3203DEN2015 2012-10-04 2013-10-04 IN2015DN03203A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261709871P 2012-10-04 2012-10-04
PCT/US2013/063503 WO2014055893A1 (en) 2012-10-04 2013-10-04 Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates

Publications (1)

Publication Number Publication Date
IN2015DN03203A true IN2015DN03203A (en) 2015-10-02

Family

ID=50435480

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3203DEN2015 IN2015DN03203A (en) 2012-10-04 2013-10-04

Country Status (13)

Country Link
US (1) US20150307596A1 (en)
EP (1) EP2903450A4 (en)
JP (1) JP2015535215A (en)
CN (1) CN105208876A (en)
AU (1) AU2013326897A1 (en)
CA (1) CA2886996A1 (en)
HK (1) HK1213148A1 (en)
IL (1) IL238111A0 (en)
IN (1) IN2015DN03203A (en)
MX (1) MX2015004258A (en)
RU (1) RU2015116883A (en)
SG (1) SG11201502430QA (en)
WO (1) WO2014055893A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399609B1 (en) 2005-08-24 2015-03-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
SG176068A1 (en) 2009-06-03 2011-12-29 Immunogen Inc Conjugation methods
RS58367B1 (en) 2011-03-29 2019-03-29 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
RU2018122734A (en) 2012-10-04 2018-07-24 Иммуноджен, Инк. USE OF PVDF MEMBRANES FOR CLEANING CONJUGATES OF CELL-BINDING AGENT-CYTOTOXIC AGENT
GB201616758D0 (en) * 2016-10-03 2016-11-16 Ge Healthcare Bio Sciences Ab Novel chromatography media
CN108549763B (en) * 2018-04-09 2021-06-01 电子科技大学 Charge exchange collision MCC method for numerical simulation of ion thruster

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ533657A (en) * 2002-01-03 2008-01-31 Smithkline Beecham Corp Methods for the preparation of immunoconjugates, in particular maytansinoids conjugated to a monoclonal antibody
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US20060182750A1 (en) * 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing stable drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
EP2399609B1 (en) * 2005-08-24 2015-03-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
SG176068A1 (en) * 2009-06-03 2011-12-29 Immunogen Inc Conjugation methods
RS58367B1 (en) * 2011-03-29 2019-03-29 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process

Also Published As

Publication number Publication date
AU2013326897A1 (en) 2015-05-07
CA2886996A1 (en) 2014-04-10
US20150307596A1 (en) 2015-10-29
RU2015116883A (en) 2016-11-27
EP2903450A1 (en) 2015-08-12
HK1213148A1 (en) 2016-06-30
JP2015535215A (en) 2015-12-10
SG11201502430QA (en) 2015-04-29
MX2015004258A (en) 2015-09-25
CN105208876A (en) 2015-12-30
IL238111A0 (en) 2015-05-31
WO2014055893A1 (en) 2014-04-10
EP2903450A4 (en) 2016-05-11

Similar Documents

Publication Publication Date Title
IN2015DN03202A (en)
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
MX2021005426A (en) Cyclodextrin and antibody-drug conjugate formulations.
PH12015500243A1 (en) Glycoconjugation processes and compositions
MX2016017355A (en) Lipid comprising docosapentaenoic acid.
NZ708727A (en) Conjugate compounds
IN2015DN03203A (en)
MX2015005792A (en) Anti apob antisense conjugate compounds.
MD20150091A2 (en) Anti-viral compounds
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
IN2015DN03327A (en)
MX2013000958A (en) Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma.
MX347882B (en) Improved process for preparing (3e,7e)-homofarnesol.
PH12014502032A1 (en) Treatment of brain cancer
MX357284B (en) Quinone compounds for treating ape1 mediated diseases.
NZ742805A (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
PH12014501367A1 (en) Processes for making magnolol and derivatives thereof
PH12014501327A1 (en) Processes for making magnolol analogs
GEP201706708B (en) Isoxazolidine derivatives
WO2014159501A3 (en) Processes for preparing tetrahydroisoquinolines
IN2012DE00826A (en)
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate
IN2014KN02683A (en)
IN2013CH04314A (en)
SG10201803880TA (en) Stable compositions of neuroactive peptides